Pancreatic cancer is highly effective in evading the immune response. Model simulations qualitatively agree with data in cancer treatments. We emphasize the crucial role of the state of the immune system in treatments. Immuno-modulatory drugs are effective in a narrow window of immune responses. 
Introduction
Pancreatic cancer is the fourth most common cause of cancerrelated death in the United States. It has extremely poor prognosis, with a one-year survival rate of about 25% and a five-year survival rate less than 5% (Hariharan et al., 2008) . One reason for its poor prognosis is that pancreatic cancer typically develops over a period of 10-15 years, but most often does not cause symptoms until it is advanced and has metastasized (Corbo et al., 2012) . Currently surgery remains the treatment approach with the best chance of cure, but only localized cancer is suitable for surgical intervention. Furthermore only about 20% of patients present with localized disease at the time of diagnosis (Koido et al., 2011; Hackert and BŸchler, 2013) . The most common histologic subtype of pancreatic cancer, which is the subject of this paper, is pancreatic ductal adenocarcinoma.
The immune system has the capability to detect tumor cells by recognition of their tumor specific antigens and subsequent elimination by cytotoxic CD8þ T cells (CTLs) or natural killer (NK) cells (Fukunaga et al., 2004; Ryschich et al., 2005; Vivier et al., 2011) . However, tumor cells may use a variety of means to escape immune recognition and elimination. For example, they may attract myeloid derived suppressor cells (MDSCs), anti-inflammatory macrophages or T regulatory cells to block the activation of CTLs and NK cells, or in some cases induce them to undergo apoptosis (Steer et al., 2010; Liyanage et al., 2002) . Tumors also have the ability to render T cells anergic or to engage inhibitory checkpoint ligands (i.e. PD1) on the cell surface (Steer et al., 2010) .
The progression of pancreatic cancer depends on the tumor microenvironment which is dictated not only by pancreatic cancer cells (PCCs) but also by various host cells including but not limited to pancreatic stellate cells (PSCs), CTLs, tumor associated macrophages M1 (pro-inflammatory) and M2 (anti-inflammatory), and MDSCs. These cells communicate with each other through a large array of cytokines and other soluble factors (Fig. 1) . For pancreatic ductal adenocarcinoma, PCCs are epithelial cells that have been documented to secrete multiple factors including TGFβ which promotes activity and growth of PSCs (Gaspar et al., 2007; Omary et al., 2007; Apte et al., 1999) and GMCSF which promotes recruitment of MDSC and induces M2 polarization (Bayne et al., 2012; Pylayeva-Gupta et al., 2012) . PSCs are myofibroblast-like cells that represent a major component of the tumor-associated stroma. These cells can act to enhance the growth and metastatic properties of tumor cells, and more recently have been recognized as having an immune modulatory potential (Bachem et al., 2008; Mace et al., 2013) . These direct tumor-promoting properties may be particularly influenced by the growth factor EGF which promotes the proliferation of PCCs (Phillips, 2012) . They also produce cytokines including TGFβ, IL6, and MCSF which enhance MDSC function and M2-polarization and promote an immunosuppressive microenvironment (Shek et al., 2002; Omary et al., 2007; Mace et al., 2013) . Tumor-associated macrophages are also highly relevant within the tumor microenvironment. These cells can switch type between pro-inflammatory M1 and anti-inflammatory M2 which have distinct phenotypic characteristics (Kurahara et al., 2011) . For example, M1-polarized macrophages typically produce high levels of cytokines such as IL12 and low levels of IL10, whereas M2-polarized macrophages produce high levels of IL10 and low levels of IL12. Together this complex network of cells can act upon CTLs or other cells that elicit cytotoxic activity against tumors. These anti-tumor immune effectors typically displayed upregulated cytotoxic activity upon exposure to IL12 which conversely is downregulated by IL10. For a recent review see Roshani et al. (2014) .
Recent data indicate that the M1 to M2 transition may be important for the progression and therapeutic response in patients with pancreatic cancer. Overall, the transition from M1 and M2 is promoted by the cytokines TGFβ, IL6, M-CSF and GM-CSF secreted by PCCs and PSCs (Koido et al., 2011; Bayne et al., 2012; Gnerlich et al., 2010) . This results in increased production of cytokines such as IL10, decreased production of IL12, and consequently decreased CTL activity (Koido et al., 2011) and increased cancer growth or metastasis. Together, this diverse collection of cells and soluble factors in the tumor microenvironment can influence the behavior of tumor-associated macrophages (TAMs). In the interaction network described in Fig. 1 , we adopted the simplification where MDSC is included together with M2 as one compartment. For example, both cell types produce IL10 which block the activation of CTLs by IL12. However, MDSC can also down-regulate production of IL12 by macrophages (Bunt et al., 2009 ), and we account for this implicitly by simply decreasing the production rate of IL12.
In recent years, many mathematical models have been developed to describe the interaction between cancer cells and the immune system (de Pillis et al., 2005 (de Pillis et al., , 2006 (de Pillis et al., , 2013 Galante et al., 2012; Wilson and Levy, 2012; Radunskaya and Hook, 2012; Robertson-Tessi et al., 2012) . However, no mathematical model has been developed to address how such interactions lead to cancer growth or regression in the context of pancreatic cancer. In this paper we develop a mathematical model for pancreatic cancer that incorporates the cancer-stroma-immune interaction and use it to explain biomedical and clinical data on clinically-relevant drug treatments that target TGFβ and EGF receptors (Deharvengt et al., 2012; Ellermeier et al., 2013; Kurahara et al., 2011) . The resulting model is based on the network in Fig. 1 and describes the dynamic interactions among prominent cells and cytokines in terms of a system of differential equations. The model adequately reproduces multiple observed immunotherapy treatment experiments, but, more importantly, provides a generic insight on the effect of such treatments that may also be applied to other tumors.
The organization of the paper is as follows. In Section 2, we introduce the full model and simplifications of it based on separation of time scales involved in pancreatic cancer growth. In Section 3, we show that our model can explain experimental data on TGFβ silencing therapy and EGFR blocking therapy (Ellermeier et al., 2013; Deharvengt et al., 2012) . In Section 4, we show that the model suggests differential responses to drug treatment given different parameters of the immune response. Finally, we discuss our results and open problems in Section 5.
The mathematical model
The simplest mathematical model for pancreatic cancer must include PCCs, PSCs, macrophages and T cells. This is so because cancer cells and PSCs affect the phenotype of macrophages ðM1-M2Þ, and T cells must be introduced because they are the cells that kill cancer cells and their activation depends on M1 cells. However, in order to understand the underlying biology, we first develop a more detailed model, "the full model", that also includes primary cytokines by which the above five types of cells communicate with each other. Then we use quasi-steady-state approximation to simplify the full model to the "reduced model" consisting of four ODEs with variables PCCs, PSCs, T, and the ratio of M1 to M2.
Variables and notations
Based on the interaction network in Fig. 1 
The full model
We start by introducing the equations for the tumor cells. Growth of many organisms under normal conditions follows the "universal law", that is, the total body mass m grows with a rate am p ð1 Àðm=M 0 Þ 1 À p Þ, where the exponent p % 3=4, a is the growth rate and M 0 is the maximum size of the organism (West et al., 2001) . Recently it was shown that cancer tissue growth can be described similarly, with the exponent p ranges from 2/3 to 1, depending on the growth conditions and the fractal topology of the neoplastic vascular system (Guiot et al., 2006) . In this model, we adopt this description and choose p ¼ 3=4 to model the growth of cancer cells; choosing slightly different values of p had no significant effect on the results. In addition, PSC promotes cancer growth through various cytokines, thus we represent the cancer growth rate as the sum of the basal growth rate, k c , and the enhancement by PSC, μ c P. We further denote the maximum cancer density by C 0 . Since IL10 can reduce the ability of CTLs in killing cancer cells (Wang et al., 2011; Itakura et al., 2011) , we assume the rate of removal of cancer cells to be a decreasing function of IL10. Based on these considerations, the evolution of the cancer cell density can be described by the following equation:
The first term on the right-hand side (RHS) models cancer growth, and the second term models the removal of cancer cells by T cells. Pancreatic stellate cells (PSCs) are the resident myofibroblastlike cells in pancreas ducts. PSCs can be activated by cytokines such as TGFβ, and activated PSCs can secrete more TGFβ. Compared to cancer cells, PSCs are more sparse in the pancreas ducts, thus we model their growth using a logistic function. The equation for PSCs is
where k p Pð1 À P=P 0 Þ is the basal growth rate in the absence of TGFβ, ðμ p T β =ðK p þ T β ÞÞPð1 À P=P 0 Þ is the TGFβ induced growth rate, and λ p is the death rate of the PSC. The term μ p T β =ðK p þ T β Þ is used here to model the saturation limited effect of TGFβ. The pro-inflammatory and anti-inflammatory macrophages M1 and M2 can be attracted to the site of pancreatic cancer, undergo apoptosis, and switch type. The transition from M1 to M2 is mediated by cytokines such as TGFβ ðT β Þ, IL6 (I 6 ), MCSF (S), and GMCSF (G). The equations for M1 and M2 are dM 1 dt
Here k 1 and k 2 are the influx rates, λ 1 and λ 2 are the death rates of M1 and M2 respectively, the transition rate α from M2 to M1 is assumed to be constant, and the transition rate from M1 to M2 is assumed to depend on TGFβ, IL6, MCSF, and GMCSF linearly. Finally, CTLs in the lymph nodes travel to the cancer site upon a cue. They are then activated by CD4 þ T cells, which in turn are activated by IL-12 in conjunction with major histocompatibility complex class II (MHC II) presented on the surface of macrophages, and the latter process is inhibited by IL-10. For simplicity, we model the dynamics of CTLs (T) in pancreatic cancer by the following equation:
We next describe the equations for the cytokines. For simplicity, we assume that the cytokines are produced by corresponding cells at a constant rate, and they undergo a natural decay with constant rates. According to Fig. 1 , we have
Here the k's and μ β are the production rates and the λ's are the degradation rates. We note that each cytokine is produced by a single cell type, except for TGF-β which is produced by both tumor cells and pancreatic cells. Most parameters in (Eqs. (6)-11) are not known experimentally. However, as we shall see in the next section, these parameters will not appear in our simplified model, because they will be lumped together.
The reduced model
Pancreatic cancer growth involves multiple time scales: the growth of cancer cells occurs on a time scale of months to years in vivo and weeks to months in vitro; the recruitment of macrophages and T cells occurs on a time scales of days to weeks; and the secretion and decay of cytokines occur on a time scale of seconds to hours. In order to understand the dynamics of cancer growth, we simplify the model using quasi-steady-state approximations for the cytokine concentrations. Under this assumption, Eqs. (6)- (11) become
Substituting these expressions into (Eqs.
(1)-5), we obtain the following simplified system for the cell dynamics:
dP dt
where
Here the combined parameters ν c and ν p describe the contribution of cancer cells and the PSCs to the growth of the PSC population, and γ c and γ p describe how the transition from M1 to M2 depends on cancer cells and the PSCs. We note that the density of PSCs (P) is much smaller than the density of cancer cells (C) in the duct in pancreatic cancer (Feig et al., 2012) . We assume that the secretion rate of TGFβ by PSC, k β , is not bigger than that by cancer cells, μ β . Therefore in Eq. (13) the term ν p P is much smaller than ν c C and, to simplify the model, we neglect it. By redefining K p to be K p =ν c , Eq. (13) can be written as
The dynamics of pancreatic ductal adenocarcinoma are affected by the macrophage population types and number. In order to analyze the system, it is more convenient to change variables to represent this dependence. Specifically, the total number of macrophages M ¼ M 1 þ M 2 , and the fraction of pro-inflammatory macrophages R ¼ M 1 =M are critical markers of the status of the immune system. Accordingly, we introduce a change of variable from M1 and M2 to M and R. In these new variables, we have
Adding (Eqs. (14) and 15)), and using Eq. (18), we obtain dM dt
For R, we can use the chain rule to obtain dR dt
Since there are no known differences in macrophages death rates, we assume that
We notice that the total number of macrophages, M, is independent of R and saturates over a period of weeks, which is set by the parameter λ M . However, in pancreatic cancer the balance between the two types of macrophages can change slowly, as P and C grow. Based on this observation of separation of time scales, we further simplify the model by approximating M by its quasi-steady-state
We also simplify (Eqs. (12) and 16) using (18). We set
Using these notations the death term in Eq. (12) becomes
Similarly, the growth term in (16) becomes
Substituting these back into (12) and (16) and dropping the primes for simplicity of notation, the model is then simplified to a system of four ODEs,
where k r ¼ k 1 λ M =k M þα and λ r ¼ λ M þ α. We call this system the reduced model for pancreatic cancer and use it to explain biomedical and clinical data in the next section.
Simulation results on drug treatments
In this section, we investigate whether the proposed model shows cancer dynamics that agree with experimental data on treatments that involve immune activation, TGFβ silencing and EGFR silencing. Ellermeier et al. (2013) studied the effect of treatments that involve TGFβ silencing and immune activation through RIG-I pathway on pancreatic cancer, and reported the survival time distribution for populations of pancreatic cancer patients without treatments and with different combinations of treatments (see Fig. 2A ). For patients without treatments, the mean survival time (MST) is short, the variance of MST is small (black curve). For patients with single treatment using TGFβ silencing or immune activation, the MST increases and its range is broader (orange and green). For patients with both treatments, the MST and its variance are significantly larger than those of single treatments (red).
Combination of TGFβ silencing and immune activation treatment
To investigate whether our model agrees with these experimental data, we simulated our model for a population of pancreatic cancer patients and investigated how the survival time distribution depends on the parameters of the model that correspond to TGFβ and immune activation treatments. We assume that the main difference among these patients is the strength of their adaptive immune responses. For each treatment we created a population of 50 patients such that each patient has a different λ c which is proportional to the killing rate of cancer cells by CTLs.
Specifically, we took these λ c 's to be a geometric sequence between 10 À 9 and 10 À 6:5 . Simulations show that using different distributions of λ c yields qualitatively similar results as in Fig. 2B .
For patients without any treatment, we used all parameters as in Table 1 ; for patients with TGFβ silencing treatment, we reduced γ c , γ p and μ p to 10% of their values in Table 1 ; and for patients with immune activation, we increased k t to be twice of its value in Table 1 . In all simulations, we set the initial cancer cell density to be 200 cells per mL, and initial values for the other three variables at their quasi-steady states. We assumed that the survival time of a patient is the time for the cancer cell density to reach a threshold density and we take this threshold to be 5000 cells per mL. Fig. 2B demonstrates the simulated survival time distribution for different cases of treatments, and the results agree with the experimental data qualitatively.
Combinations of EGFR silencing and TGFβ sequestration treatments
In the microenvironment of pancreatic cancer, elevated EGF and its receptor and TGFβ have been observed (Korc, 1998) . In a report from Deharvengt et al. (2012) it is shown that concomitant treatment with EGFR silencing RNAs and TGFβ sequestration molecule sTβ RII showed enhanced benefit in controlling ASPC-1 pancreatic cancer cell growth in mice (Fig. 3A) . In this section, we use the reduced model to investigate how combinations of treatments of EGFR knockout and TGFβ silencing affect tumor size. As in Deharvengt et al. (2012) , we compare four different cases. The first is without any treatment, the second is with EGFR silencing only, the third is with TGFβ sequestration only, and the fourth is with both treatments. For simulations without treatment, we use parameters specified in Table 1 . To model EGFR silencing treatment, we take μ c to be 0.7 times of the value in Table 1 to take into account the blockage of the enhancement of PCC proliferation by PSC produced EGF. We did not completely block the influence of PSC to PCC because there exists other PSC secreted cytokines in the cancer microenvironment that promote cancer cell growth. To model TGFβ treatment, we set γ p ¼ γ c ¼ μ p ¼ 0 in the reduced model to eliminate the effects of TGFβ. We plot the evolution of the cancer size in these four different cases in Fig. 3B , colored as black, blue, red, and green. These simulations show that combinations of treatment is significantly better than any single treatment and the dynamics of cancer size resulting from our model is in qualitative agreement with experimental data.
In Deharvengt et al. (2012) , it is also reported that for some other cancer cell lines, e.g., T3M4, the effect of simultaneously targeting EGFR and TGFβ markedly suppressed HER2, resulting in actually larger tumor load than in the case of targeting only EGFR or TGFβ alone. This situation, although not simulated here, can be achieved using our model by changing corresponding parameters that implicitly relate to HER2 expression.
Since some of the parameters of our model are only estimated up to the order of magnitudes, we only claim qualitative fit of our model (Figs. 2B and 3B) to the data in Ellermeier et al. (2013) and Deharvengt et al., 2012 (Figs. 2A and 3A) . On the other hand, we shall analyze in the next section how the model results depend on the parameters. Table 1 ; magenta: ppp-RNA; green: OH-TGFβ; red: both. (For interpretation of the references to color in this figure caption, the reader is referred to the web version of this article.)
Analysis on the drug efficacy and the immune response
The varied response of patients to drug treatment, as shown, for example, in Section 3.1, is likely due to the varied immune response of patients. In the model (Eqs. (25)-28), the immune system response can be characterized by the parameters γ p , γ c and λ c . In this section, we show that the immune system, characterized by γ p , γ c , λ c is affected by immunotherapy only when these parameters fall within a specific regime, that is, there is a specific "window of opportunity" for an effective immune response. Our analysis is based on the reduced model (Eqs. (25)-28), which highlights two feedback loops as shown in Fig. 4 . The first is a positive feedback loop that involves mutual enhancement of PCCs (C) and PSCs (P), and the second is a double negative feedback loop (i.e. a positive feedback loop) involving mutual inhibition of the cancer and the immune system, i.e., the C and P complex (top) and the R and T complex (bottom). Specifically, PCCs and PSCs promote M2 polarization and thus reduce R, and R upregulates T, which in turn down-regulate C.
The cancer-immune interaction leads to the sensitive response of the system to the parameters of γ c , γ p and λ c . The parameters γ c and γ p represent the effect of PCCs and PSCs on the polarization of the macrophages, and λ c is the killing rate of cancer cells by T cells.
In the absence of the negative feedback from C and P to R, we have γ c ¼ γ p ¼ 0. In this case, the steady state cancer size slowly decreases as λ c increases (Fig. 5A, red dashed) . However, in the presence of the negative feedback, the steady state cancer size shows a switch-like behavior as λ c increases (Fig. 5A , blue solid): for large λ c , the tumor size is small; for small λ c , the cytokines have no effect; for intermediate λ c , however, there is a sharp change in tumor size. suggests that treatments which aim to change these parameters are potentially effective. For example, one can increase λ c by boosting the immune response, decrease γ p and γ c by blocking TGF-beta or IL6, or decreasing μ p and μ c by blocking EGFR or TGFβ.
Second, it suggests that such treatments can only be effective if corresponding parameters are perturbed in the "right" way. To better understand the "switch-like" behavior, we solve the steady-state equations of the reduced model. By explicitly solving the steady states of P, R and T from (26)- (28) and substituting into (25), we obtain that the non-zero steady state cancer size is determined by the nontrivial solution C of the following equation: Bifurcation analysis suggests that two saddle node bifurcations occur near two points of λ c , namely, λ 1 ¼8.77eÀ 7 and λ 2 ¼1.07eÀ 6. For λ c o λ 1 or λ c 4 λ 2 , there is only one solution of C, and for λ 1 oλ c o λ 2 , there are three solutions. Furthermore, the upper branch ðλ c oλ 2 Þ and the lower branch ðλ c 4 λ 1 Þ are stable, while the middle branch which connects the two is unstable. The upper branch represents a more aggressive tumor than the lower branch. As λ c increases from small values up to λ 2 , the tumor will remain in the aggressive state. However, as soon as λ c exceeds λ 2 , there is a sharp drop in the size of the steady state cancer, and the system will evolve towards the lower branch. If λ c now decreases, the tumor will remain in the nonaggressive state (the lower branch), until λ c becomes smaller than λ 1 , in which case the tumor size will jump back to the aggressive state. This suggests that if we apply a treatment to boost the immune response so that λ c increases, the treatment will be most effective if the patient's parameter λ c is near λ 2 , i.e., a small increase of the immune response will sharply reduce the tumor from the aggressive state to the nonaggressive state; for other values of λ c in the upper branch, a small increase in the immune system will provide only minimal improvement.
Conclusions and discussion
In this paper we have developed a mathematical model of pancreatic cancer. The model involves PCCs, PSCs, immune cells M1, M2, MDSC and CTL, and cytokines EGF, TGFβ, IL6, MCSF, GMCSF, IL10 and IL12. Although M2 and MDSC are two different types of cells, both suppress the function of CTLs and NK cells. For simplicity we have combined M2 and MDSC into one compartment. We have simulated the model in two cases of treatments, where experimental data were available. We represented the effect of the drug by a change in some of the rate parameters. For example, in EGFR silencing treatment, taking account of the blockage of the enhancement of PCC proliferation by PSC produced EGF, we did not completely block the influence of PSC to PCC because there exist other PSC secreted cytokines in the cancer environment that promotes cancer cell growth, although they were not included explicitly in the model. Thus, this treatment is expressed by decreasing the parameter μ c in Eq. (25) to 0:7μ c , not by completely eliminating it.
In Section 4 we emphasized the important role of the state of the immune system in drug treatment. If the immune system is weak (e.g., in the sense that the killing rate of CTLs, λ c , is small), as in the case of a patient with organ transplant or with HIV/AIDs, or if the immune system is very strong (e.g., λ c is very large), then treatment is not effective. Many papers describe the role of cytotoxic chemotherapy (Burrisrd et al., 1997; Von Hoff et al., 2011; Heinemann et al., 2013; Hosein et al., 2013) . NAB-PaclitaxelGemcitabine perhaps is one of the more promising chemotherapeutic approaches tested to date. Other chemotherapeutic approaches including an intense FOLFIRINOX regimen has proven effective at debulking tumors, to make curative resection more likely (Heinemann et al., 2013; Bekaii-Saab and Goldberg, 2013) . As patient data from such treatments become available, our model could be further refined to reflect the results of these treatments, and then be used to develop hypotheses on optimal scheduling of treatments.
The proposed model, as are all such models, is obviously a highly simplified description of the biological complexity. It does not include the spatial structure of the tumor or the metabolic elements limiting the tumor growth. It does not include important aspects of immune response, such as T regulatory cells (Tregs), CD4 þ T cells, and the complex interactions between Th1, Th2 and Th17 cells, which may also be relevant to pancreatic cancer development and progression (Beatty et al., 2011) . It does not account for stromal cells and hypoxia. We also lumped cytokines into generic groups based on the overall homology in function. Introducing all these cells and their associated cytokines would indeed make the model more comprehensive; however, because of the sparsity of experimental data for pancreatic cancer, not necessarily more useful.
The risk of cancer depends on two factors, growth/proliferation and invasion/metastasis, and the balance of the two primarily depends on the specific cancer. For example, in cutaneous melanoma diagnosed at early stages, growth is a major factor for prognosis: if the tumor is still within the dermis, it can be excised with a reduced chance for relapse; but if the growth has reached the subcutaneous tissue (5 mm depth) then metastasis is more likely and survival may be only a matter of months. Typically, in pancreatic cancer, metastasis has already taken place at the time of diagnosis, and the mean survival time is only a few months (see Fig. 2 ). Although our mathematical model is described in terms of tumor cell proliferation, it represents, to some extent, the total risk associated with pancreatic cancer, since the more cancer cells there are, the greater the possibility of metastasis is.
